Bath Savings Trust Co Raised Edwards Lifesciences (EW) Holding; Shorts at Prothena Plc Ord WI (PRTA) Raised By 1.48%

Prothena Corporation Plc Ord WI (NASDAQ:PRTA) had an increase of 1.48% in short interest. PRTA’s SI was 5.52M shares in December as released by FINRA. Its up 1.48% from 5.44 million shares previously. With 461,500 avg volume, 12 days are for Prothena Corporation Plc Ord WI (NASDAQ:PRTA)’s short sellers to cover PRTA’s short positions. The stock decreased 0.81% or $0.3 during the last trading session, reaching $36.77. About 314,875 shares traded. Prothena Corporation plc (NASDAQ:PRTA) has risen 41.05% since December 23, 2016 and is uptrending. It has outperformed by 24.35% the S&P500.

Bath Savings Trust Co increased Edwards Lifesciences Corp (EW) stake by 116.62% reported in 2017Q3 SEC filing. Bath Savings Trust Co acquired 7,240 shares as Edwards Lifesciences Corp (EW)’s stock rose 25.80%. The Bath Savings Trust Co holds 13,448 shares with $1.47M value, up from 6,208 last quarter. Edwards Lifesciences Corp now has $23.81 billion valuation. The stock decreased 0.71% or $0.81 during the last trading session, reaching $112.49. About 917,133 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since December 23, 2016 and is uptrending. It has underperformed by 1.29% the S&P500.

Among 27 analysts covering Edwards Lifesciences Corp (NYSE:EW), 20 have Buy rating, 1 Sell and 6 Hold. Therefore 74% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $122.50’s average target is 8.90% above currents $112.49 stock price. Edwards Lifesciences Corp had 90 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Outperform” rating given on Wednesday, April 26 by RBC Capital Markets. Bank of America upgraded Edwards Lifesciences Corporation (NYSE:EW) on Thursday, July 27 to “Buy” rating. The firm earned “Equal-Weight” rating on Thursday, April 7 by Barclays Capital. The firm earned “Sell” rating on Wednesday, July 27 by Citigroup. The stock has “Buy” rating by RBC Capital Markets on Friday, September 1. Stifel Nicolaus maintained Edwards Lifesciences Corporation (NYSE:EW) on Wednesday, October 26 with “Buy” rating. RBC Capital Markets maintained Edwards Lifesciences Corporation (NYSE:EW) on Monday, October 2 with “Buy” rating. The firm has “Buy” rating by Suntrust Robinson given on Thursday, January 21. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, June 27. The firm has “Market Perform” rating by Northland Capital given on Tuesday, April 5.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $1.41 billion. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

Since September 25, 2017, it had 0 buys, and 7 sales for $2.97 million activity. The insider Zago Wagner M. sold 900 shares worth $63,000. Kinney Gene G. sold $196,000 worth of Prothena Corporation plc (NASDAQ:PRTA) on Thursday, September 28. Selkoe Dennis J. had sold 3,500 shares worth $224,583. HENNEY CHRISTOPHER S sold $63,000 worth of stock. Shares for $1.21M were sold by Nickerson Tara. The insider Walker Karin L sold 1,500 shares worth $105,000.